FocalTherics Posts Record Q2 HIFU Revenue of $12.7M–$13.2M, Up 34–39% YoY, and Pivots to Pure-Play Robotic Focal Therapy
FOCL has more than doubled off its 52-week low of $1.26.
Summary
FocalTherics reported preliminary Q2 2026 HIFU revenue of $12.7–$13.2 million, up 34–39% year-over-year, and announced the reclassification of its legacy ESWL and Distribution segments as discontinued operations, becoming a pure-play robotic focal therapy company. The investor presentation details expansion into large BPH and endometriosis markets.
Key Events · Earnings and Guidance · FOCL
-
Record Q2 HIFU Revenue
Preliminary Q2 2026 HIFU revenue reached $12.7–$13.2 million, a 34–39% year-over-year increase, fueled by 13 Focal One system sales (up 44% YoY) and a 47% rise in U.S. procedure volume.
-
Strategic Shift to Pure-Play Focal Therapy
With the ESWL and Distribution segments reclassified as discontinued operations, FocalTherics becomes a pure-play robotic focal therapy company, concentrating on the high-growth HIFU segment.
-
Gross Margin Expansion
HIFU gross margin improved to 54–56%, up 3–5 percentage points year-over-year, reflecting operating leverage and a favorable mix.
-
Cash Position and Operating Loss
Cash, cash equivalents, and short-term investments totaled $21.5 million as of June 30, 2026; the HIFU segment's operating loss of $7.5–$8.5 million reflects continued investment in growth and new indications.
Analysis · FOCL · Industrial Applications And Services
Preliminary Q2 HIFU revenue surged 34–39% year-over-year to $12.7–$13.2 million, while gross margins expanded to 54–56%. By reclassifying its legacy ESWL and Distribution businesses as discontinued operations, FocalTherics transforms into a pure-play robotic focal therapy company. The accompanying investor presentation maps out a substantial addressable market expansion into BPH and endometriosis, with a combined TAM exceeding 4.3 million procedures and $10 billion in revenue. With $21.5 million in cash and an operating loss of $7.5–$8.5 million, the company is funding growth while advancing new indications and histotripsy technology. This filing delivers the first hard numbers on the HIFU segment's standalone performance and the strategic pivot, offering investors a clearer view of the core business's trajectory.
At the time of this filing, FOCL was trading at $4.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $227.9M. The 52-week trading range was $1.26 to $6.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.